Showing results (241-250 of 389) with videos related to

Sort By:
Pageof 39
Oncotarget|December 15, 2015
HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancerNaoki Takegawa, Kimio Yonesaka, Kazuko Sakai, et al.
Japanese Journal of Clinical Oncology|February 24, 2018
Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subsetKatsuyuki Kiura, Fumio Imamura, Hiroshi Kagamu, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2013
Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lungHidemi Kiyota, Isamu Okamoto, Masayuki Takeda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trialMark A Socinski, Igor Bondarenko, Nina A Karaseva, et al.
Plos One|January 14, 2012
SRPX2 is a novel chondroitin sulfate proteoglycan that is overexpressed in gastrointestinal cancerKaoru Tanaka, Tokuzo Arao, Daisuke Tamura, et al.
Cancer|April 6, 2013
Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancerYoshiko Urata, Isamu Okamoto, Masayuki Takeda, et al.
Annals of Surgical Oncology|March 1, 2019
A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell CarcinomaTaichi Matsubara, Kazuki Takada, Koichi Azuma, et al.
Molecular Cancer Therapeutics|August 7, 2010
Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumorsIsamu Okamoto, Hiroyasu Kaneda, Taroh Satoh, et al.
Lung Cancer (Amsterdam, Netherlands)|March 19, 2010
Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancerIsamu Okamoto, Koji Takeda, Haruko Daga, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2021
Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitorsShinkichi Takamori, Kazuki Takada, Mototsugu Shimokawa, et al.
Pageof 39